학술논문
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
Document Type
Article
Author
Source
The Lancet; November 1996, Vol. 348 Issue: 9036 p1212-1215, 4p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Orthotopic liver transplantation in patients positive for hepatitis B virus (HBV) DNA is associated with a high reinfection rate, even with hepatitis B immunoglobulin (HBIG) prophylaxis. Nucleoside analogues that inhibit hepatitis B replication in patients with chronic hepatitis B could prevent reinfection after transplantation. The aim of this study was to analyse the efficacy and safety of prophylaxis both before and after transplantation with the nucleoside analogue lamivudine, without HBIG, in patients undergoing liver transplantation.